UVA sunscreens
This article was originally published in The Rose Sheet
Executive Summary
FDA reiterates outstanding questions on the critical wavelength method, or modified Diffey, in a July 16 letter to the Cosmetic, Toiletry and Fragrance Association. The letter is a formal response to CTFA's April 1996 proposal that the method be accepted as a test for UVA protection. In its response, FDA asks technical questions related to the use of instruments and area to be tested in the critical wavelength proposal, as well as the minimal erythemal dose of 1 J/cm2 measurement. The agency also repeats its request for additional UVA testing data. The queries are a restatement of those raised with CTFA during a Jan. 27 "feedback" meeting (1"The Rose Sheet" Feb. 1, p. 8)